Drugging the epigenome in the age of precision medicine
Abstract Background Modulating the epigenome has long been considered a potential opportunity for therapeutic intervention in numerous disease areas with several approved therapies marketed, primarily for cancer. Despite the overall promise of early approaches, however, these drugs have been plagued...
Main Authors: | Taylor Feehley, Charles W. O’Donnell, John Mendlein, Mahesh Karande, Thomas McCauley |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-01-01
|
Series: | Clinical Epigenetics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13148-022-01419-z |
Similar Items
-
The Epigenomics of Pituitary Adenoma
by: Blake M. Hauser, et al.
Published: (2019-05-01) -
Precise epigenomic editing with a SunTag-based modular epigenetic toolkit
by: Subhrangshu Guhathakurta, et al.
Published: (2022-12-01) -
MYCN and the Epigenome
by: Stanley eHe, et al.
Published: (2013-01-01) -
Racial disparities in liver cancer: Evidence for a role of environmental contaminants and the epigenome
by: Adriana C. Vidal, et al.
Published: (2022-08-01) -
Epigenomics of Pancreatic Cancer: A Critical Role for Epigenome-Wide Studies
by: Rahul R. Singh, et al.
Published: (2019-01-01)